B-MS made to work for new NICE nod for Opdivo

13 October 2017

Weeks after its use was recommended by the National Institute for Health and Care Excellence (NICE) for some patients with lung cancer, now Opdivo (nivolumab) is to be paid for in certain cases of head and neck cancer in England.

Once more the immuno-oncology drug, developed by Bristol-Myers Squibb (NYSE: BMY), is to be provided through the Cancer Drugs Fund (CDF) after the cost-effectiveness watchdog changed its stance once the US pharma major had agreed to a discount and to provide further data on its effectiveness.

It will now be available for patients with head and neck cancer who have not responded to chemotherapy within six months, and the cancer has spread to other parts of the body.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK